ABSTRACT
Consensus grows for abandoning the ancestral strain to improve immune responses.
Subject(s)
COVID-19 Vaccines , COVID-19 , Immunization, Secondary , Immunogenicity, Vaccine , SARS-CoV-2 , Humans , Antibodies, Viral/immunology , COVID-19 Vaccines/immunology , Vaccination , SARS-CoV-2/immunologyABSTRACT
Virus biology, widespread vaccination may be driving down risk of persistent symptoms.
Subject(s)
Post-Acute COVID-19 Syndrome , SARS-CoV-2 , Vaccination , Humans , Post-Acute COVID-19 Syndrome/epidemiology , Post-Acute COVID-19 Syndrome/prevention & control , Post-Acute COVID-19 Syndrome/virologyABSTRACT
Scientists and regulators seek new course amid uncertainty.
Subject(s)
COVID-19 Vaccines , COVID-19 , Immunization, Secondary , Influenza, Human , Humans , COVID-19/prevention & control , COVID-19 Vaccines/administration & dosage , Influenza, Human/prevention & controlABSTRACT
Pandemic propels international efforts to understand incidence of rare side effects.
Subject(s)
COVID-19 Vaccines , Mass Vaccination , COVID-19 Vaccines/adverse effects , Databases, Factual , Humans , Mass Vaccination/adverse effects , Pandemics , RiskABSTRACT
With benefits unclear, some scientists question new round of shots for young people.
Subject(s)
COVID-19 Vaccines , COVID-19 , Immunization, Secondary , Myocarditis , Adolescent , Humans , COVID-19/prevention & control , Immunization, Secondary/adverse effects , Young Adult , Adult , Myocarditis/epidemiology , Myocarditis/etiology , United StatesABSTRACT
Initiative to explore whether coronavirus lingers in patients.
Subject(s)
Antiviral Agents , Biomedical Research , COVID-19 Drug Treatment , COVID-19 , Antiviral Agents/therapeutic use , COVID-19/complications , Humans , Post-Acute COVID-19 SyndromeABSTRACT
Study implicates lack of key hormone, battle-weary immune cells, and awakened viruses.
Subject(s)
COVID-19 , COVID-19/blood , COVID-19/immunology , Humans , Hydrocortisone/blood , T-Lymphocytes/immunology , Post-Acute COVID-19 SyndromeABSTRACT
Scientists strive to unravel what is driving disabling symptoms.
Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Coronavirus Protease Inhibitors/therapeutic use , Lactams/therapeutic use , Leucine/therapeutic use , Nitriles/therapeutic use , Proline/therapeutic use , Ritonavir/therapeutic use , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , COVID-19/virology , Clinical Trials as Topic , Coronavirus Protease Inhibitors/administration & dosage , Coronavirus Protease Inhibitors/pharmacology , Cytidine/administration & dosage , Cytidine/analogs & derivatives , Cytidine/pharmacology , Cytidine/therapeutic use , Humans , Hydroxylamines/administration & dosage , Hydroxylamines/pharmacology , Hydroxylamines/therapeutic use , Lactams/administration & dosage , Lactams/pharmacology , Leucine/administration & dosage , Leucine/pharmacology , Nitriles/administration & dosage , Nitriles/pharmacology , Proline/administration & dosage , Proline/pharmacology , Ritonavir/administration & dosage , Ritonavir/pharmacology , SARS-CoV-2/drug effects , TabletsABSTRACT
The article talks about antiviral pills that prevent symptoms and death if taken early in infection for Covid-19 infection produced by Pfizer and Merck & Co.